Lactic Acid Bacteria Composition for Gut-Brain Neurological Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurological and inflammatory diseases, particularly mental disorders and neurodegenerative diseases, are inadequate and often come with significant side effects, while existing natural product compositions have limited efficacy.

Innovation Solution

Development of novel lactic acid bacteria, specifically Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98, isolated from human and mouse feces, which inhibit neurodegenerative disease-inducing factors and reduce anxious and depressive behaviors, and are used in pharmaceutical compositions for prevention and treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments for mental disorders and neurological diseases are used, then therapeutic effects are achieved, but serious side effects occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces lactic acid bacteria as an intermediary substance that mediates between the gut and brain through the gut-brain axis. These bacteria produce neurotransmitters and anti-inflammatory compounds that indirectly treat neurological and mental disorders without the direct toxic effects of conventional drugs, thereby achieving therapeutic effects while minimizing side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent utilizes lactic acid bacteria that can be administered as probiotics or through food sources. These biological agents are naturally occurring, can be replenished continuously through diet or supplementation, and degrade safely in the body without accumulating toxic residues, providing a safer alternative to long-term pharmaceutical use

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Object-affected harmful factors

If natural product treatments are used for neurological diseases, then side effects are reduced, but effectiveness is insufficient

Engineering Contradiction:

Improveside effectsVSAvoidtherapeutic effect

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent employs composite biological systems by combining multiple strains of lactic acid bacteria with different functional properties. Some strains produce neurotransmitters like GABA and serotonin, while others produce anti-inflammatory compounds or short-chain fatty acids. This composite approach synergistically enhances therapeutic effectiveness while maintaining the safety profile of natural products

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent optimizes various parameters of the lactic acid bacteria including strain selection, cultivation conditions, dosage forms, and administration routes. By adjusting these parameters, the therapeutic effectiveness is enhanced to match or exceed conventional treatments while preserving the inherent safety advantages of natural biological agents

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If drugs such as antidepressants are used, then treatment is provided, but cardiovascular diseases and suicide risks increase

Engineering Contradiction:

Improvetreatment availabilityVSAvoidcardiovascular diseases and suicide risks

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The lactic acid bacteria serve as natural intermediaries that produce neurotransmitters and modulate immune responses through the gut-brain axis. This indirect mechanism of action provides antidepressant and anxiolytic effects without the cardiovascular side effects and suicide risks associated with conventional pharmaceuticals, while maintaining treatment accessibility

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent leverages the natural metabolic activities of lactic acid bacteria in the gut to produce beneficial compounds that counteract neurological and mental disorders. By converting the natural gut microbiota into a therapeutic agent, the treatment achieves pharmaceutical-like effectiveness without the harmful side effects, turning a potentially problematic area (gut health) into a therapeutic advantage

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260102442A1Novel lactic acid bacteria and use thereof

Publication Date: 2026.04.16 NAVIPHARM CO LTD

AI summary

The present invention relates to a novel lactic acid bacterium, and more particularly, to a composition comprising Lactobacillus reuteri NK33 (KCCM12090P) or Bifidobacterium adolescentis NK98 (KCCM12297P), which is the novel lactic acid bacterium, useful in preventing and treating a neurological mental disease or an inflammatory disease.Also, the present invention relates to a composition for diagnosing a neurological mental disease, comprising a preparation for measuring a level of an intestinal microorganism, a kit comprising the same, and a method for diagnosing the neurological mental disease, comprising a step of measuring the level of the intestinal microorganism.